Meta-analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

Breast Cancer Research and Treatment

Volumn 56, Issue 2, 1999, Pages 133-143

  Pyrhonen S ^a   Ellmen J ^b   Vuorinen, J ^b   Gershanovich, M ^c   Tominaga, T ^d   Kaufmann, M ^e   Hayes, D F ^f  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

^b ORION CORPORATION   (Finland)

^c N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^f GEORGETOWN UNIVERSITY   (United States)

Author keywords

Advanced breast cancer; Predictive factors; Tamoxifen; Toremifene

Indexed keywords

ANTIESTROGEN; ESTROGEN RECEPTOR; TAMOXIFEN; TOREMIFENE;

ADVANCED CANCER; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; EDEMA; FEMALE; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; METASTASIS; NAUSEA; POSTMENOPAUSE; PREDICTION; PRIORITY JOURNAL; SIDE EFFECT; SWEATING; TREATMENT FAILURE; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VERTIGO; VOMITING;

EID: 0032724683     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/a:1006250213357     Document Type: Article

References (49)

1. Jaiyesimi IA, Buzdar AU, Decker DA and Hortobagyi GN: Use of tamoxifen for breast cancer: Twenty-eight years later. J Clin Oncol 13: 513-529, 1995
2. Osborne CK: Receptors, In: Harris J, Hellman S, Henderson I et al. (eds) Breast Diseases. Lippincott, Philadelphia, PA, 1991, pp 301-325
3. Henderson IC: Endocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC et al. (eds) Breast Diseases, Lippincott, Philadelphia, PA, 1991. pp 559-603
4. Early breast cancer trialists collaborative group: Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339: 1-15, 1992
5. Goldhirsch A. Wood WC, Senn H-J et al.: Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Instit 87: 1441-1445, 1995
6. Love RR: Prospects for antiestrogen chemoprevention of breast cancer. J Natl Cancer Inst 82: 18-22, 1990
7. Powles TJ, Hardy JK, Ashley SE et al.; A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for preventing breast cancer. Br J Cancer 60: 126-131, 1990
8. Kangas L, Kallio S, Blanco G, Grönroos M, Kallio S, Karjalainen A, Perilä M, Södervall M, Toivola R: A new triphenylethylene compound, FC-1157a. II. Antitumor effects. Cancer Chemother Pharmacol 17: 109-114, 1986
9. Kangas L: Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol 31: 143-146, 1992
10. di Salle E, Zaccheo T, Ornati G: Antiestrogenic and antitumor properties of the new triphenylethylene derivative toremifene in the rat. J Steroid Biochem 36: 203-206, 1990
11. IARC monographs on the evaluation on the carcinogenic risk to humans. Some Pharmaceutical Drugs. IARC Press Lyon, France 66, 1996
12. Saarto T, Blomqvist C, Välimäki M et al.: Clodronate improves bone mineral density in postmenopausal breast cancer patients treated with adjuvant antiestrogens. Br J Cancer 75: 602-605, 1997
13. Saarto T, Blomqvist C, Ehnholm C et al.: Antiatherogenic effects of adjuvant antiestrogens: a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with nodepositive breast cancer. J Clin Oncol 14: 429-433, 1996
14. Jordan VC, Dix CJ, Naylor KE, Prestwitch G, Rowsby L: Nonsteroidal antiestrogens: their biological effects and potential mechanism of action. J Toxicol Environ Health 4: 363-390, 1978
15. Wärri AM, Huovinen RL, Laine AM et al.: Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J Natl Cancer Inst 85: 1412-1418, 1993
16. Lahti EI, Knip M, Laatikainen TJ: Plasma insulin-like growth factor I and its binding proteins 1 and 3 in postmenopausal patients with breast cancer receiving long term tamoxifen. Cancer 74: 618-624, 1994
17. Rankumar T, Adler S: Differential positive and negative transcriptional regulation by tamoxifen. Endocrinol 136: 536-542, 1995
18. Wiseman H: Tamoxifen: new membrane-mediated mechanisms of action and therapeutic advances. TIPS 15: 83-89, 1994
19. Su H-D, Mazzei GJ, Vogler WR, Kuo JF: Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/Calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem Pharmacol 34: 3649-3653, 1985
20. Valverde MA, Mintenig GM, Sepúlveda FV: Differential effects of tamoxifen and J on three distinguishable chloride currents activated in T84 intestinal cells. Eur J Physiol 425: 552-554, 1993
21. DeGregorio M, Ford JM, Benz CC, Wiebe VJ: Toremifene: pharmacological and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7: 1359-1364, 1989
22. 1 acid glycoprotein. Eur J Cancer 26: 432-436, 1990
23. Ahotupa M, Hirsimäki P, Hirsimäki Y, Pärssinen R, Mäntylä E: Alterations of drug metabolizing and antioxidant enzyme activities during tamoxifen-induced hepatocarcinogenesis in the rat. Carcinogenesis 15: 863-868, 1994
24. Thangaraju M, Ezhilarasi R, Sachdanandam P: Effect of tamoxifen on erythrocyte membrane lipids, lipid peroxides, and antioxidative enzymes in breast cancer women. Cancer Biochem Biophys 14: 297-302, 1995
25. Kendall ME, Rose DP: The effects of diethylstilbesterol, tamoxifen, and toremifene on estrongen-inducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114: 127-131, 1992
26. Számel I, Hindy I, Vincze B et al.: Influence of toremifene on the endocrine regulation in breast cancer patients. Eur J Cancer 30A: 154-158, 1994
27. Robinson SP, Jordan VC: Antiestrogenic action of toremifene on hormone-dependent, -independent, and heterogenous breast tumor growth in the athymic mouse. Cancer Res 49: 1758-1762, 1989
28. Moon RC, Steele VE, Keller GJ, Thomas CF, Detrisae CJ, Mehta RG, Lubet RA: Chemoprevention of MNU-induced mammary tumorigenesis by hormone response modifiers: toremifene, RU 16117, tamoxifen, aminoglutethimide and progesterone. Anticancer Res 14: 889-894, 1994
29. Valavaara R, Pyrhönen S, Heikkinen M, Rissanen P, Blanco G, Thölix E, Nordman E, Taskinen P, Holsti L, Hajha A: Toremifene, a new antiestrogenic compound, for treatment of advanced breast cancer. Phase II study. Eur J Cancer Clin Oncol 24: 785-790, 1988
30. Pyrhönen S, Valavaara R, Heikkinen M, Rissanen P, Blanco G, Nordman L, Holsti RL, Hajba A: Treatment of advanced breast cancer with 20 mg toremifene, a phase II study. Preliminary communication. J Steroid Biochem 36: 227-228, 1990
31. Hietanen T, Baltina D, Johansson R et al.: High dose toremifene (240 mg daily) is effective as first line hormonal treatment in advanced breast cancer - An ongoing phase II multicentcr Finnish-Latvian cooperative study. Breast Cancer Res Treat 16: 37-40, 1990
32. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SAA, Dombernowsky P: Toremifene and tamoxifen in advanced breast cancer a double-blind cross-over trial. Breast Cancer Res Treat 25: 57-63, 1993
33. Hayes DF, van Zyl JA, Hacking A et al.: Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556-2566, 1995
34. Pyrhönen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy J, Vuorinen J, Hajba A: Comparison or toremifene and tamoxifen in postmenopausal patients with advanced breast cancer: a randomised double blind, the 'Nordic' phase III study. Br J Cancer 76: 270-277. 1997
35. Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J: A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 45: 251-262, 1997.
36. Kaufmann M, Sindermann H, Burk K, Hilgard P: Multicentric phase II trial of efficacy and tolerance of toremifene (FC 1157a) in patients with hormonally pretreated advanced breast cancer. Orion Corporation, Orion Pharma study report 5/032, 22.2.1993
37. Nomura Y, Tominaga T, Abe O, Izuo M, Ogawa N. Clinical evaluation of NK 622 (toremifene citrate) in advanced or recurrent breast cancer a comparative study by a double blind method with tamoxifen. Jpn J Cancer Chemother 20: 247-258, 1993
38. Miller AB, Hoogstarten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
39. Oyen MM, Greech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP: Toxicity and response criteria of Eastern Cooperative Oncology Group. AM J Oncol 5: 649-655, 1982
40. Kinbaru Shuppan (ed): General Rules for Clinical and Pathological Recordings of Breast Cancer, 9th edn. Japanese Breast Cancer Society, Tokyo, 1988 (in Japanese)
41. WHO Adverse Reaction Dictionary: WHO collaborating center for international drug monitoring, Uppsakt. Sweden. March 1988
42. Whitehead A, Whitehead J: A general parametric approach to the meta-analysis of randomized clinical trials. Statistics in Medicine 10: 1665-1677, 1991
43. Bratherton DG, Brown CH, Buchanan R et al.: A comparison of two doses of tamoxifen (Nolvadex*) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer 50: 199-205, 1984
44. Mouridsen H, Palshof T, Patterson J, Battersby L: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5: 131-141, 1978
45. Homesley HD, Shemano I, Gains R et al.: Antiestrogenic potency of toremifene and tamoxifen in postmenopausal women. Am J Clin Oncol 16: 117-122, 1993
46. Kendall ME, Rose DP: The effects of diethylstilbestrol, tamoxifen, and toremifene on estrogen-iducible hepatic proteins and estrogen receptor proteins in female rats. Toxicol Appl Pharmacol 114: 127-13, 1992
47. Kuukasjärvi T, Kononen J, Helin H, Holli K, Isola J: Loss of estrogen receptor in recurrent breast cancer associated with poor response to endocrine therapy. J Clin Oncol 14: 2584-2589, 1996
48. Legler CM, Shemano I, Schoenfelder J, Hayes DF. Effect of prior tamoxifen (TAM) on response to TAM & toremifene (TOR) in metastatic breast cancer. Proc Am Soc Clin Oncol 14: 91a, 1995 (abstr)
49. Howell A, Mackintosh I, Jones M, Redford J, Wagstaff J, Sellwood RA: The definition of the 'No Change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Eur J Cancer Clin Onc 24: 1567-1572, 1988